Vitiligo and Psoriasis: Can You Have Both?

Yes — you can have both vitiligo and psoriasis, and the co-occurrence is more frequent than chance would predict. Both are immune-mediated skin conditions, though their mechanisms differ, and the patient who has both faces distinct challenges in management. The treatment intersection, however, offers a clinically interesting opportunity.

How common is the overlap?

Studies report psoriasis in approximately 2–5% of vitiligo patients — somewhat elevated compared to general population psoriasis prevalence of about 2–3%. The co-occurrence rate is not as dramatic as some other vitiligo comorbidities, but it is documented consistently enough to take seriously.

Different immune mechanisms

Understanding the co-occurrence requires understanding that vitiligo and psoriasis, while both immune-mediated, use different arms of the immune system:

Vitiligo is driven primarily by CD8+ cytotoxic T cells and interferon-gamma signalling — a Th1-type immune response. The JAK1/2 pathway carries the interferon-gamma signal that drives melanocyte destruction.

Psoriasis is driven primarily by the IL-17/IL-23 axis — a Th17-type immune response — as well as Th1 involvement. This is why biologics targeting IL-17 and IL-23 are so effective for psoriasis.

The fact that both conditions involve dysregulated T cell activity in the skin, even via different pathways, explains the co-occurrence — shared genetic susceptibility in immune regulation genes creates vulnerability to both. But the different dominant pathways mean treatments targeting one condition do not automatically address the other.

The JAK inhibitor treatment opportunity

Here is where the overlap becomes clinically interesting: JAK inhibitors modulate multiple immune signalling pathways, including both the JAK-STAT/interferon pathway relevant to vitiligo and pathways involved in psoriasis.

Upadacitinib (Rinvoq) is approved for psoriatic arthritis and has Phase 3 trial data for vitiligo. A patient with both vitiligo and psoriasis (particularly psoriatic arthritis) is a strong candidate for oral upadacitinib, which may provide benefit for both conditions. Baricitinib has similar dual potential in principle, though its approval landscape differs.

Topical Opzelura has shown some evidence in plaque psoriasis as well as vitiligo, though its primary approvals are for vitiligo and atopic dermatitis. For patients with co-localised psoriasis and vitiligo patches, this is worth discussing with a dermatologist.

What psoriasis biologics do to vitiligo

Many psoriasis patients are on IL-17 inhibitors (secukinumab, ixekizumab), IL-23 inhibitors (risankizumab, guselkumab), or TNF inhibitors (adalimumab, etanercept). What do these do for co-existing vitiligo?

The evidence is limited, but case reports and small series suggest:

• TNF inhibitors (adalimumab) have case reports of both improving vitiligo and triggering vitiligo de novo — a paradoxical effect similar to that seen with other biologics
• IL-17/IL-23 inhibitors have less documented interaction with vitiligo, given the different immune pathway involved
• No psoriasis biologic has established evidence for vitiligo benefit

If you are on a psoriasis biologic and have vitiligo, inform your dermatologist — the interaction context matters for treatment planning.

Distinguishing the two conditions

In the same patient, distinguishing vitiligo patches from psoriasis plaques is usually straightforward:

• Vitiligo: Chalk-white, sharply demarcated, no scale, asymptomatic
• Psoriasis: Erythematous (red), well-demarcated, with silvery scale, often itchy

Both can affect the scalp, elbows, knees, and other body areas — but their appearance is distinct enough that clinical differentiation is usually clear.

A nuanced situation: post-psoriatic hypopigmentation — lighter skin after psoriasis plaques resolve — can be confused with vitiligo. This hypopigmentation is usually not as stark white as vitiligo and lacks the specific depigmentation pattern. A Wood’s lamp examination can help: vitiligo patches fluoresce distinctly under Wood’s lamp, while post-inflammatory hypopigmentation typically does not show the same pattern.

Practical management

With both conditions:

1. Coordinate care — ideally a single dermatologist manages both, or two specialists communicate about overlapping treatment plans
2. Consider JAK inhibitors if either condition is moderate to severe — particularly upadacitinib if psoriatic arthritis is also present
3. Discuss biologic interaction with your dermatologist before starting new psoriasis biologics if vitiligo is co-existing and being actively treated
4. Track both conditions with photographs — the vitiligo progress tracking guide principles apply to monitoring both skin conditions
5. Sun protection is important for vitiligo patches (no UV protection in depigmented skin) and complex for psoriasis (some psoriasis benefits from controlled UV while vitiligo patches need protection)

The vitiligo treatment options comparison and the tacrolimus vs Opzelura comparison give context for topical treatment choices when managing both conditions.